<p>Xenon Pharmaceuticals（納斯達克代碼：XENE - 獲取免費報告）於週四發佈了其財報。該生物製藥公司報告本季度每股收益為（$1.31），低於市場共識預期的（$1.20），差距為（$0.11），據 Zacks 報道。在去年同期，該公司每股收益為（$0.84）。</p>
<p>獲取 <strong>Xenon Pharmaceuticals</strong> 的提醒：</p>
<h2>Xenon Pharmaceuticals 價格表現</h2>
<ul>
<li>布里斯托爾 - 邁爾斯斯奎布的重大收購：在兩筆生物技術交易中投資 181 億美元</li>
</ul>
<p>週四，XENE 股票上漲 0.34 美元，達到 44.92 美元。該股票交易量為 709,123 股，而其平均交易量為 917,995 股。該股票市值為 34.7 億美元，市盈率為-11.55，貝塔值為 0.96。Xenon Pharmaceuticals 的股價在過去一年內最低為 26.74 美元，最高為 46.60 美元。該股票的 50 日移動平均價格為 42.51 美元，200 日移動平均價格為 40.94 美元。</p>
<h2>分析師評級上調與下調</h2>
<p>多位股票分析師對 XENE 股票發表了評論。Chardan Capital 在 11 月 19 日的研究報告中將 Xenon Pharmaceuticals 的股票評級上調至 “強力買入”。摩根大通在 1 月 9 日的報告中將 Xenon Pharmaceuticals 的目標價格從 60.00 美元上調至 62.00 美元，並給予該股票 “超配” 評級。富國銀行在 12 月 11 日的報告中將 Xenon Pharmaceuticals 的目標價格從 44.00 美元上調至 48.00 美元，並給予該公司 “超配” 評級。Needham &amp; Company LLC 在 11 月 4 日的研究報告中重申了 “買入” 評級，並對 Xenon Pharmaceuticals 的股票設定了 55.00 美元的目標價格。最後，Stifel Nicolaus 在 2 月 10 日的報告中對 Xenon Pharmaceuticals 設定了 66.00 美元的目標價格。兩位研究分析師給予該股票 “強力買入” 評級，十一位給予 “買入” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，Xenon Pharmaceuticals 目前的平均評級為 “買入”，共識目標價格為 55.17 美元。</p>
<p><strong>獲取我們對 Xenon Pharmaceuticals 的最新股票分析</strong></p>
<h2>Xenon Pharmaceuticals 的內部交易</h2>
<p>在其他 Xenon Pharmaceuticals 的新聞中，首席執行官 Ian Mortimer 在 1 月 2 日的交易中出售了 40,000 股公司股票。該股票以平均價格 44.43 美元出售，總交易額為 1,777,200.00 美元。出售完成後，首席執行官直接持有公司 6,000 股股票，價值約 266,580 美元。此次交易使其持股減少了 86.96%。該出售在向 SEC 提交的文件中披露，相關文件可通過 SEC 網站訪問。內部人士在上個季度共出售了 65,302 股公司股票，價值 2,924,128 美元。公司內部人士持有 4.07% 的股票。</p>
<h2>機構投資者對 Xenon Pharmaceuticals 的看法</h2>
<p>機構投資者最近調整了對該公司的持股。Freestone Grove Partners LP 在第三季度收購了 Xenon Pharmaceuticals 的新股份，價值約 271,000 美元。Virtus Investment Advisers LLC 在第四季度將其在 Xenon Pharmaceuticals 的持股增加了 74.0%。Virtus Investment Advisers LLC 目前持有 6,037 股該生物製藥公司的股票，價值 271,000 美元，此前在該期間內又購買了 2,568 股。Magnetar Financial LLC 在第四季度收購了 Xenon Pharmaceuticals 的新股份，價值約 231,000 美元。Cibc World Markets Corp 在第四季度收購了 Xenon Pharmaceuticals 的新股份，價值約 225,000 美元。最後，Mackenzie Financial Corp 在第四季度收購了 Xenon Pharmaceuticals 的新股份，價值 210,000 美元。機構投資者和對沖基金持有公司 95.45% 的股票。</p>
<h2>Xenon Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Xenon Pharmaceuticals Inc 是一家臨牀階段的生物製藥公司，致力於發現和開發針對中樞和外周神經系統離子通道的新型小分子藥物。該公司的研究重點集中在神經和疼痛疾病上，包括癲癇、偏頭痛和神經性疼痛，通過調節關鍵的離子通道蛋白來恢復正常的神經功能。Xenon 的科學平台利用離子通道生物學和基於結構的藥物設計的進展，識別和優化具有潛在改進的安全性和療效特徵的治療候選藥物。</p>
<p>該公司的產品管線包括多個臨牀前和臨牀項目。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Xenon Pharmaceuticals</li>
<li>預測 iPhone 的人説買入這三家公司</li>
<li>解鎖：埃隆·馬斯克的下一個大 IPO</li>
<li>用這四個簡單步驟 “防止” 你的銀行賬户受到影響</li>
<li>這讓我感到憤怒</li>
<li>沒有人談論的免費股票推薦</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVORQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVORQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Xenon Pharmaceuticals 嗎？</h2>
<p>在考慮 Xenon Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Xenon Pharmaceuticals 並不在名單上。</p>
<p>雖然 Xenon Pharmaceuticals 目前在分析師中獲得了 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Xenon制藥

<p>Xenon Pharmaceuticals（納斯達克代碼：XENE）報告的季度每股收益為（$1.31），低於分析師預期的（$1.20），差距為$0.11。與去年同期的每股收益（$0.84）相比有所下降。該股上漲$0.34，報$44.92，市值為$34.7 億。分析師對該股的平均評級為 “買入”，一致目標價為$55.17。內部交易方面，首席執行官 Ian Mortimer 出售了 40,000 股。機構投資者持有該公司 95.45% 的股份</p>

<p>Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) posted its earnings results on Thursday. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.11), Zacks reports. During the same period last year, the company earned ($0.84) EPS.</p>
<div class="lb-trans"><p>Xenon Pharmaceuticals（納斯達克代碼：XENE - 獲取免費報告）於週四發佈了其財報。該生物製藥公司報告本季度每股收益為（$1.31），低於市場共識預期的（$1.20），差距為（$0.11），據 Zacks 報道。在去年同期，該公司每股收益為（$0.84）。</p>
</div><p>Get <strong>Xenon Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Xenon Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Xenon Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Xenon Pharmaceuticals 價格表現</h2>
</div><ul>
<li>Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals</li>
</ul>
<div class="lb-trans"><ul>
<li>布里斯托爾 - 邁爾斯斯奎布的重大收購：在兩筆生物技術交易中投資 181 億美元</li>
</ul>
</div><p>Shares of XENE stock traded up $0.34 on Thursday, reaching $44.92. 709,123 shares of the stock were exchanged, compared to its average volume of 917,995. The stock has a market cap of $3.47 billion, a PE ratio of -11.55 and a beta of 0.96. Xenon Pharmaceuticals has a one year low of $26.74 and a one year high of $46.60. The stock has a 50 day moving average price of $42.51 and a 200 day moving average price of $40.94.</p>
<div class="lb-trans"><p>週四，XENE 股票上漲 0.34 美元，達到 44.92 美元。該股票交易量為 709,123 股，而其平均交易量為 917,995 股。該股票市值為 34.7 億美元，市盈率為-11.55，貝塔值為 0.96。Xenon Pharmaceuticals 的股價在過去一年內最低為 26.74 美元，最高為 46.60 美元。該股票的 50 日移動平均價格為 42.51 美元，200 日移動平均價格為 40.94 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調與下調</h2>
</div><p>A number of equities analysts have commented on XENE shares. Chardan Capital upgraded shares of Xenon Pharmaceuticals to a &#34;strong-buy&#34; rating in a research report on Wednesday, November 19th. JPMorgan Chase &amp; Co. boosted their target price on Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, January 9th. Wells Fargo &amp; Company raised their price target on Xenon Pharmaceuticals from $44.00 to $48.00 and gave the company an &#34;overweight&#34; rating in a report on Thursday, December 11th. Needham &amp; Company LLC reiterated a &#34;buy&#34; rating and issued a $55.00 price objective on shares of Xenon Pharmaceuticals in a research report on Tuesday, November 4th. Finally, Stifel Nicolaus set a $66.00 target price on Xenon Pharmaceuticals in a report on Tuesday, February 10th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Xenon Pharmaceuticals presently has an average rating of &#34;Buy&#34; and a consensus price target of $55.17.</p>
<div class="lb-trans"><p>多位股票分析師對 XENE 股票發表了評論。Chardan Capital 在 11 月 19 日的研究報告中將 Xenon Pharmaceuticals 的股票評級上調至 “強力買入”。摩根大通在 1 月 9 日的報告中將 Xenon Pharmaceuticals 的目標價格從 60.00 美元上調至 62.00 美元，並給予該股票 “超配” 評級。富國銀行在 12 月 11 日的報告中將 Xenon Pharmaceuticals 的目標價格從 44.00 美元上調至 48.00 美元，並給予該公司 “超配” 評級。Needham &amp; Company LLC 在 11 月 4 日的研究報告中重申了 “買入” 評級，並對 Xenon Pharmaceuticals 的股票設定了 55.00 美元的目標價格。最後，Stifel Nicolaus 在 2 月 10 日的報告中對 Xenon Pharmaceuticals 設定了 66.00 美元的目標價格。兩位研究分析師給予該股票 “強力買入” 評級，十一位給予 “買入” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，Xenon Pharmaceuticals 目前的平均評級為 “買入”，共識目標價格為 55.17 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Xenon Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 Xenon Pharmaceuticals 的最新股票分析</strong></p>
</div><h2>Insider Transactions at Xenon Pharmaceuticals</h2>
<div class="lb-trans"><h2>Xenon Pharmaceuticals 的內部交易</h2>
</div><p>In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 40,000 shares of the business's stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $44.43, for a total transaction of $1,777,200.00. Following the completion of the sale, the chief executive officer directly owned 6,000 shares of the company's stock, valued at approximately $266,580. The trade was a 86.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold a total of 65,302 shares of company stock valued at $2,924,128 in the last quarter. 4.07% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他 Xenon Pharmaceuticals 的新聞中，首席執行官 Ian Mortimer 在 1 月 2 日的交易中出售了 40,000 股公司股票。該股票以平均價格 44.43 美元出售，總交易額為 1,777,200.00 美元。出售完成後，首席執行官直接持有公司 6,000 股股票，價值約 266,580 美元。此次交易使其持股減少了 86.96%。該出售在向 SEC 提交的文件中披露，相關文件可通過 SEC 網站訪問。內部人士在上個季度共出售了 65,302 股公司股票，價值 2,924,128 美元。公司內部人士持有 4.07% 的股票。</p>
</div><h2>Institutional Investors Weigh In On Xenon Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對 Xenon Pharmaceuticals 的看法</h2>
</div><p>Institutional investors have recently modified their holdings of the business. Freestone Grove Partners LP acquired a new stake in shares of Xenon Pharmaceuticals in the 3rd quarter valued at approximately $271,000. Virtus Investment Advisers LLC grew its holdings in Xenon Pharmaceuticals by 74.0% during the fourth quarter. Virtus Investment Advisers LLC now owns 6,037 shares of the biopharmaceutical company's stock valued at $271,000 after purchasing an additional 2,568 shares during the period. Magnetar Financial LLC bought a new stake in Xenon Pharmaceuticals in the fourth quarter valued at approximately $231,000. Cibc World Markets Corp bought a new stake in Xenon Pharmaceuticals in the fourth quarter valued at approximately $225,000. Finally, Mackenzie Financial Corp acquired a new stake in Xenon Pharmaceuticals in the fourth quarter worth $210,000. Institutional investors and hedge funds own 95.45% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者最近調整了對該公司的持股。Freestone Grove Partners LP 在第三季度收購了 Xenon Pharmaceuticals 的新股份，價值約 271,000 美元。Virtus Investment Advisers LLC 在第四季度將其在 Xenon Pharmaceuticals 的持股增加了 74.0%。Virtus Investment Advisers LLC 目前持有 6,037 股該生物製藥公司的股票，價值 271,000 美元，此前在該期間內又購買了 2,568 股。Magnetar Financial LLC 在第四季度收購了 Xenon Pharmaceuticals 的新股份，價值約 231,000 美元。Cibc World Markets Corp 在第四季度收購了 Xenon Pharmaceuticals 的新股份，價值約 225,000 美元。最後，Mackenzie Financial Corp 在第四季度收購了 Xenon Pharmaceuticals 的新股份，價值 210,000 美元。機構投資者和對沖基金持有公司 95.45% 的股票。</p>
</div><h2>Xenon Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Xenon Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.</p>
<div class="lb-trans"><p>Xenon Pharmaceuticals Inc 是一家臨牀階段的生物製藥公司，致力於發現和開發針對中樞和外周神經系統離子通道的新型小分子藥物。該公司的研究重點集中在神經和疼痛疾病上，包括癲癇、偏頭痛和神經性疼痛，通過調節關鍵的離子通道蛋白來恢復正常的神經功能。Xenon 的科學平台利用離子通道生物學和基於結構的藥物設計的進展，識別和優化具有潛在改進的安全性和療效特徵的治療候選藥物。</p>
</div><p>The company's pipeline comprises multiple preclinical and clinical programs.</p>
<div class="lb-trans"><p>該公司的產品管線包括多個臨牀前和臨牀項目。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Xenon Pharmaceuticals</li>
<li>The Man Who Predicted the iPhone Says Buy These 3 Companies</li>
<li>Unlocked: Elon Musk’s Next Big IPO</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>This makes me furious</li>
<li>The free stock picks nobody’s talking about</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Xenon Pharmaceuticals</li>
<li>預測 iPhone 的人説買入這三家公司</li>
<li>解鎖：埃隆·馬斯克的下一個大 IPO</li>
<li>用這四個簡單步驟 “防止” 你的銀行賬户受到影響</li>
<li>這讓我感到憤怒</li>
<li>沒有人談論的免費股票推薦</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVORQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=XENE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Xenon Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Xenon Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Xenon Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Xenon Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Xenon Pharmaceuticals 並不在名單上。</p>
</div><p>While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Xenon Pharmaceuticals 目前在分析師中獲得了 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Xenon 製藥（NASDAQ:XENE）公佈季度財報，每股收益比預期低 0.11 美元